Are you Dr. Nowak?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 25 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1000 E Mountain Blvd
Wilkes-Barre, PA 18711Phone+1 570-825-1000Fax+1 570-271-6578- Is this information wrong?
Summary
- Dr. Miroslawa Nowak, MD is a rheumatologist in Wilkes-Barre, Pennsylvania. She is currently licensed to practice medicine in Pennsylvania. She is affiliated with Geisinger Medical Center.
Education & Training
National Institutes of Health Clinical CenterFellowship, Rheumatology, 2000 - 2003
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1996 - 1999
Pomeranian Academy of Medicine in SzczecinClass of 1990
Certifications & Licensure
PA State Medical License 2003 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
- Fellow (FACR) American College of Rheumatology
Publications & Presentations
PubMed
- Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial.Laure Gossec, Laura C Coates, Alexis Ogdie, Jiyoon Choi, Brandon Becker, Joe Zhuo, Thomas Lehman, Ayanbola Elegbe, Philip J Mease, Atul Deodhar, Vibeke Strand, Mirosla...> ;Arthritis Care & Research. 2024 Mar 26
- 1 citationsEvaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging...Conaghan, P., Du, S., Luo, Y., Landis, J., Pachai, C., Fura, A., Catlett, I., Grasela, D., Østergaard, M., Nowak, M.> ;The Lancet. Rheumatology. 2023 May 1
- 75 citationsEfficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.Philip J Mease, Atul A Deodhar, Désirée van der Heijde, Frank Behrens, Alan J Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, Subhashis Banerjee> ;Annals of the Rheumatic Diseases. 2022 Jun 1
- Join now to see all
Authored Content
- Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled TrialOctober 2020
Professional Memberships
- Fellow
Hospital Affiliations
Geisinger Medical CenterDanville, Pennsylvania
